Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06630585 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

Study acronym: AID-JUNCT
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 26, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 3 sitesv6
  2. Study sites: 1 to 3
    • Collaborators: 1 to 3
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary and study completion dates: Dec 2025 to Jun 2026
    • Start date changed from estimate of Nov 2024 to Feb 14, 2025
    • Secondary endpoints: 47 to 8
    • Site details revised
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Bern
73 trials monitored
See 3 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 1 Diabetes
886 trials monitored
See 40 trials at risk
Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D. This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.
Trial Details
NCT Number NCT06630585
Lead Sponsor University of Bern
Collaborators: Kantonsspital Olten, Luzerner Kantonsspital, Clinique des Grangettes, Chêne-Bougeries
Conditions
(from sponsor)		 Type 1 Diabetes (T1D)
Related terms Diabetes Mellitus, Type 1
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov